Trial · NCT02120352
Participant flow84
How many started, completed or left each group, period by period.
1 to 20 of 84
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Induction Period (20 Weeks) | STARTED | CAB 30 mg+ABC/3TC QD (Induction Period) | 309 | |
| Induction Period (20 Weeks) | STARTED | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | 0 | |
| Induction Period (20 Weeks) | STARTED | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | 0 | |
| Induction Period (20 Weeks) | STARTED | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) | 0 | |
| Induction Period (20 Weeks) | STARTED | Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | 0 | |
| Induction Period (20 Weeks) | STARTED | Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | 0 | |
| Induction Period (20 Weeks) | STARTED | Long-Term Follow-Up Group | 0 | |
| Induction Period (20 Weeks) | COMPLETED | CAB 30 mg+ABC/3TC QD (Induction Period) | 288 | |
| Induction Period (20 Weeks) | COMPLETED | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | 0 | |
| Induction Period (20 Weeks) | COMPLETED | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | 0 | |
| Induction Period (20 Weeks) | COMPLETED | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) | 0 | |
| Induction Period (20 Weeks) | COMPLETED | Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | 0 | |
| Induction Period (20 Weeks) | COMPLETED | Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | 0 | |
| Induction Period (20 Weeks) | COMPLETED | Long-Term Follow-Up Group | 0 | |
| Induction Period (20 Weeks) | NOT COMPLETED | CAB 30 mg+ABC/3TC QD (Induction Period) | 21 | |
| Induction Period (20 Weeks) | NOT COMPLETED | CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) | 0 | |
| Induction Period (20 Weeks) | NOT COMPLETED | CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) | 0 | |
| Induction Period (20 Weeks) | NOT COMPLETED | CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) | 0 | |
| Induction Period (20 Weeks) | NOT COMPLETED | Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period) | 0 | |
| Induction Period (20 Weeks) | NOT COMPLETED | Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02120352/flow